Skip to content

Oruka Therapeutics, Inc. ORKA Operating Cash Flow

Operating Cash Flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$1.1B-43.5%
Eli Lilly logo
Eli LillyLLY
$5.33B+220%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$2.51B-39.8%
Amgen logo
AmgenAMGN
$2.19B+57.4%
AbbVie logo
AbbVieABBV
$3.83B+134%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-$88.84M-12.2%

Other financials

Income statement

See full
Revenue-
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$4.36B+533%
Enterprise value$4.32B+690%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×
Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s operating cash flow?
Oruka Therapeutics, Inc. (ORKA) reported operating cash flow of -$23.58M in Q1 2026.
How has Oruka Therapeutics, Inc.'s operating cash flow changed year-over-year?
Oruka Therapeutics, Inc.'s operating cash flow decreased by 13.0% year-over-year, from -$20.87M to -$23.58M.
What is the long-term trend for Oruka Therapeutics, Inc.'s operating cash flow?
Over 4 years (2021 to 2025), Oruka Therapeutics, Inc.'s operating cash flow has grown at a 47.3% compound annual growth rate (CAGR), from -$18.76M to -$88.21M.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.